Pliant Therapeutics Q2 EPS $(0.70) Beats $(0.71) Estimate, Sales $248.00K Miss $880.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Pliant Therapeutics (NASDAQ:PLRX) reported Q2 losses of $(0.70) per share, beating the analyst consensus estimate of $(0.71) by 1.41%. However, the company's quarterly sales of $248.00K missed the analyst consensus estimate of $880.00K by 71.82%. This represents a 95.03% decrease over sales of $4.99M in the same period last year.
August 09, 2023 | 8:52 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Pliant Therapeutics reported better than expected Q2 EPS but significantly missed on sales.
While Pliant Therapeutics beat the EPS estimate, the significant miss on sales, which decreased by 95.03% compared to the same period last year, is likely to negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100